Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: comparator.

Patients received insulin glargine in the morning with fixed doses of metformin.

Insulin glargine plus metformin

After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin.

Patients received insulin glargine in the morning with fixed doses of glimepiride.

Insulin glargine plus glimepiride

After 24 weeks, HbA1C levels improved from 8.4±1.0% to 7.7±1.3% with insulin glargine plus glimepiride.

Patients received insulin glargine in the morning with fixed doses of both glimepiride and metformin.

Insulin glargine plus glimepiride plus metformin

After 24 weeks, HbA1C levels improved from 8.7±0.9% to 7.3±0.6% with insulin glargine plus glimepiride plus metformin.

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

VOGLI+MET

GLIME+MET

Core clinician-reference fields are available or not applicable.

Patients received twice daily doses of GLIME+VOGLI+MET-ER (1+0.2+500 mg)

GLIME+VOGLI+MET-ER

Patients received twice daily doses of GLIME+VOGLI+MET-ER (1+0.2+500 mg: Trivolib 1, 2+0.2+500 mg: Trivolib 2)

Patients received dual-drug FDC tablet of VOGLI+MET (0.2+500 mg, 0.3+500 mg)

Patients received dual-drug FDC tablet of GLIME+MET (1+500 mg, 2+500 mg)

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Triple Drug Combination Improves Glycemic Control in Type 2 Diabetes

Co-administration group

Patients received a triple fixed-dose combination of sitagliptin, metformin, and glimepiride for 16 weeks.

SITA+MET+GLIM group

Eligible patients were randomised (1:1) to receive a triple FDC of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg and glimepiride 1 mg (SITA+MET+GLIM group) or co-administration of metformin hydrochloride 1000 mg and glimepiride 2 mg (Co-administration group) for 16 weeks.

Patients received co-administered metformin and glimepiride for 16 weeks.

Patients assigned to the Co-administration group received metformin 1000 mg and glimepiride 2 mg for 16 weeks.

Metformin + glimepiride × HbA1c

Available supporting studies

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.

Triple Drug Combination Improves Glycemic Control in Type 2 Diabetes

Triple fixed-dose combination improves glycaemic control in Type 2 diabetes